アジア太平洋地域の細胞治療市場予測　2022-2030年

出版：Inkwood Research（インクウッドリサーチ）　出版年月：2022年10月

ASIA-PACIFIC CELL THERAPY MARKET FORECAST 2022-2030
アジア太平洋地域の細胞治療市場予測　2022-2030年

レポート目次　　お問合せ・ご注文　　価格・納期について

KEY FINDINGS
The Asia-Pacific cell therapy market is predicted to record a CAGR of 15.16% during the forecast period, 2022-2030. Asia-Pacific offers cost-effective manufacturing & operating units for conducting research. Also, several international corporations are increasing their investments in cell therapy in the region. In addition, many companies are collaborating to develop cell therapy products.

MARKET INSIGHTS
Singapore, Thailand, Singapore, Japan, China, India, Australia & New Zealand, and Rest of Asia-Pacific are analyzed for the Asia-Pacific cell therapy market growth assessment. Japan places a strategic emphasis on regenerative medicine due to its geriatric population and its healthcare solutions. Accordingly, the nation has spent millions of dollars on induced pluripotent stem cell research for treating sick organs. Additionally, the country has established itself as a center for induced pluripotent stem cell ((iPS cell) technology. Besides, funding agencies are offering grants to research communities to accelerate stem cell-based scientific research.
Further, companies are submitting applications to the regulatory authorities for approval to commercialize cell therapy products. For instance, Takeda Pharmaceutical Company Limited applied to the Japanese Ministry of Health, Labour, and Welfare in February 2021 to market and manufacture darvadstrocel (development code: Cx601) for treating complex perianal fistulas in Crohn’s disease (CD) patients.
In India, as per the Ministry of Health and Family Welfare, around 800,000 new cancer cases are diagnosed annually. For cancers like leukemia, CAR T-cell therapy has the potential to minimize the three-year conventional treatment using bone marrow transplant, chemotherapy, oral drugs, etc., in just three weeks. As a result, the increasing need for cell therapies is projected to influence market growth.

COMPETITIVE INSIGHTS
Some of the prominent market players are JCR Pharmaceuticals Co Ltd, Vericel Corporation, Stemedica Cell Technologies Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

目次

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING CELLULAR THERAPY CLINICAL TRIALS
3.1.2. GROWTH OF REGENERATIVE MEDICINE
3.1.3. HIGH PREVALENCE OF CHRONIC DISEASES
3.2. KEY RESTRAINTS
3.2.1. INCREASING SKILLS GAP
3.2.2. HIGH COSTS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON CELL THERAPY MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. REGULATORY FRAMEWORK
4.5. OPPORTUNITY MATRIX
4.6. VENDOR LANDSCAPE
5. MARKET BY CELL TYPE
5.1. STEM CELL
5.1.1. BONE MARROW
5.1.2. BLOOD
5.1.3. UMBILICAL CORD-DERIVED STEM CELL
5.1.4. ADIPOSE-DERIVED STEM CELL
5.1.5. OTHERS
5.2. NON-STEM CELL
6. MARKET BY THERAPY TYPE
6.1. AUTOLOGOUS
6.2. ALLOGENEIC
7. MARKET BY THERAPEUTIC APPLICATION
7.1. MALIGNANCIES
7.2. MUSCULOSKELETAL DISORDERS
7.3. AUTOIMMUNE DISORDERS
7.4. DERMATOLOGY
7.5. OTHER APPLICATIONS
8. MARKET BY END-USER
8.1. HOSPITALS & CLINICS
8.2. ACADEMIC & RESEARCH INSTITUTES
9. GEOGRAPHICAL ANALYSIS
9.1. ASIA-PACIFIC
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY DRIVERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. CHINA
9.1.5.2. JAPAN
9.1.5.3. INDIA
9.1.5.4. SOUTH KOREA
9.1.5.5. THAILAND
9.1.5.6. SINGAPORE
9.1.5.7. AUSTRALIA & NEW ZEALAND
9.1.5.8. REST OF ASIA-PACIFIC
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS
10.2. COMPANY PROFILES
10.2.1. ANTEROGEN CO LTD
10.2.2. BRISTOL MYERS SQUIBB COMPANY
10.2.3. CELLS FOR CELLS SA
10.2.4. GILEAD SCIENCES INC
10.2.5. JCR PHARMACEUTICALS CO LTD
10.2.6. KOLON TISSUEGENE INC
10.2.7. MEDIPOST CO LTD
10.2.8. MESOBLAST LIMITED
10.2.9. NUVASIVE INC
10.2.10. SMITH & NEPHEW PLC
10.2.11. STEMEDICA CELL TECHNOLOGIES INC
10.2.12. VERICEL CORPORATION

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – CELL THERAPY
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: ASIA-PACIFIC CELL THERAPY MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: ASIA-PACIFIC CELL THERAPY MARKET, BY CELL TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC CELL THERAPY MARKET, BY STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC CELL THERAPY MARKET, BY STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC CELL THERAPY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC CELL THERAPY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: ASIA-PACIFIC CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 14: ASIA-PACIFIC CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 15: KEY PLAYERS IN ASIA-PACIFIC CELL THERAPY MARKET
TABLE 16: LIST OF MERGERS & ACQUISITIONS
TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 19: LIST OF BUSINESS EXPANSIONS

LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: VENDOR LANDSCAPE
FIGURE 5: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2021
FIGURE 6: ASIA-PACIFIC CELL THERAPY MARKET, BY STEM CELL, 2022-2030 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY STEM CELL, IN 2021
FIGURE 8: ASIA-PACIFIC CELL THERAPY MARKET, BY BONE MARROW, 2022-2030 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC CELL THERAPY MARKET, BY BLOOD, 2022-2030 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC CELL THERAPY MARKET, BY UMBILICAL CORD-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC CELL THERAPY MARKET, BY ADIPOSE-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC CELL THERAPY MARKET, BY OTHERS, 2022-2030 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC CELL THERAPY MARKET, BY NON-STEM CELL, 2022-2030 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY TYPE, IN 2021
FIGURE 15: ASIA-PACIFIC CELL THERAPY MARKET, BY AUTOLOGOUS, 2022-2030 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC CELL THERAPY MARKET, BY ALLOGENEIC, 2022-2030 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021
FIGURE 18: ASIA-PACIFIC CELL THERAPY MARKET, BY MALIGNANCIES, 2022-2030 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC CELL THERAPY MARKET, BY MUSCULOSKELETAL DISORDERS, 2022-2030 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC CELL THERAPY MARKET, BY AUTOIMMUNE DISORDERS, 2022-2030 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC CELL THERAPY MARKET, BY DERMATOLOGY, 2022-2030 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC CELL THERAPY MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC CELL THERAPY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 24: ASIA-PACIFIC CELL THERAPY MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC CELL THERAPY MARKET, BY ACADEMIC & RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
FIGURE 26: ASIA-PACIFIC CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 27: CHINA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 28: JAPAN CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 29: INDIA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 30: SOUTH KOREA CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: THAILAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 32: SINGAPORE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 33: AUSTRALIA & NEW ZEALAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 34: REST OF ASIA-PACIFIC CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)